SHIRE PHARMACEUTICALS SERVICES LIMITED
Company Information
- Company Number
- 04420273
- Registered Address
- 1 Kingdom Street, London, United Kingdom, W2 6BD
- Status
- Dissolved
- Employee Count
- 4
- Turnover
- £681,000
- EBITDA
- £39,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 18 April 2002
- Nature of Business
- 96090 - Other service activities not elsewhere classified
- Industries
- Life Sciences And Medical Technology
- Region
- London
Company Review
Trend Analysis
In the first half of 2018, SHIRE PHARMACEUTICALS SERVICES LIMITED did not provide any data on their average time to pay invoices or their payment terms. However, in the second half of 2018 and the first half of 2019, they reported an average time to pay of 0 days and a standard payment period of 30 days.
Volatility Analysis
SHIRE PHARMACEUTICALS SERVICES LIMITED did not report any data in the first half of 2018, making it difficult to assess their volatility. However, in the second half of 2018 and the first half of 2019, there was no significant change in their average time to pay or their payment terms.
Summary Analysis
In the second half of 2018 and the first half of 2019, SHIRE PHARMACEUTICALS SERVICES LIMITED reported an average time to pay of 0 days and a standard payment period of 30 days. This shows a significant improvement from the first half of 2018 where no data was reported. There was also no significant change in their payment terms during this period.
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | |||||
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 |
Payment Time Trends
Payment Distribution Trends
Company Summary
SHIRE PHARMACEUTICALS SERVICES LIMITED is a leading pharmaceutical company based in the United Kingdom. The company offers a wide range of products and services in the healthcare industry, including research, development, manufacturing, and distribution of pharmaceutical drugs.
The company has a strong commitment to sustainability and has implemented various initiatives to reduce its environmental impact. This includes reducing carbon emissions, minimizing waste generation, and promoting sustainable practices throughout its operations.
Some of SHIRE's key products include treatments for rare diseases, such as Hemophilia, Hunter syndrome, and Gaucher disease. The company also offers medicines for attention deficit hyperactivity disorder (ADHD), gastrointestinal disorders, and other medical conditions.
The key people at SHIRE PHARMACEUTICALS SERVICES LIMITED include the CEO, Dr. Flemming Ornskov, and the Chairman of the Board, Susan Kilsby. They lead a team of highly skilled professionals dedicated to providing innovative and high-quality healthcare solutions.
Contact information for SHIRE PHARMACEUTICALS SERVICES LIMITED can be found on their website, www.shire.com. The registered office address is 300 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, United Kingdom.
In summary, SHIRE PHARMACEUTICALS SERVICES LIMITED is a reputable company in the healthcare industry, known for its commitment to sustainability and providing effective treatments for rare diseases and other medical conditions.
